PhamarEngine, Inc.
- Began operation in February 2003
- # of Employees: 33 (2024 Annual Report)
- Product: ONIVYDE®
- R&D Focus: Oncology
- Chairperson: Jan-Yau Hsu
- President & CEO: Hong-Ren Wang, Ph.D.
- Spokesperson: ChiHsin Chang
- HQ: Taipei, Taiwan
- Investor Contact: info@pharmaengine.com
Latest News
-
2025-11-17
ONIVYDE® with oxaliplatin, fluorouracil and leucovorin will be included in Taiwan NHI for first-line treatment of metastatic pancreatic adenocarcinoma
-
2025-10-20
PharmaEngine announces first patient dosed in PEP08 Phase I clinical trial for solid tumor cancers
-
2025-09-05
PharmaEngine recognized as one of 2025 Taiwan Best-in-Class Companies by Taiwan Institute of Directors